MWNA
SURF

Marshall Wace North America’s Surface Oncology, Inc. Common Stock SURF Stock Holding History

Marshall Wace North America’s Portfolio SURF Stock Details SURF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$286K Buy
+37,784
New +$242K ﹤0.01% 1258
2020
Q3 		– Sell
-102,565
Closed -$673K – 1550
2020
Q2 		$673K Buy
+102,565
New +$370K ﹤0.01% 862
2018
Q4 		– Sell
-19,700
Closed -$216K – 1689
2018
Q3 		$216K Buy
+19,700
New +$231K ﹤0.01% 833

Other funds holding SURF

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace North America's SURF Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Surface Oncology, Inc. Common Stock (SURF) in Q3 2021: 37,784 shares worth $286K. The stake represents ﹤0.01% of the portfolio and ranks #1258 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in SURF as recently as Q2 2020.

Marshall Wace North America first reported a position in SURF in Q3 2018 and has held it in 3 quarters since. The position peaked at $673K in Q2 2020. 91 funds tracked by Wall St. Rank hold SURF as of Q3 2021.

  • Marshall Wace North America held 37,784 shares of Surface Oncology, Inc. Common Stock worth $286K as of Q3 2021.
  • Surface Oncology, Inc. Common Stock was a new Marshall Wace North America position in Q3 2021.
  • Surface Oncology, Inc. Common Stock made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1258 holding.
  • Marshall Wace North America first reported a position in Surface Oncology, Inc. Common Stock in Q3 2018 and has held it in 3 quarters since.
  • Marshall Wace North America's Surface Oncology, Inc. Common Stock position peaked at $673K in Q2 2020.
  • 91 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.